Natural products for the treatment of depression: Insights into signal pathways influencing the hypothalamic-pituitary-adrenal axis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
ppublish
Résumé
Depression, a prevalent psychiatric malady, afflicts a substantial global demographic, engendering considerable disease burden due to its elevated morbidity and mortality rates. Contemporary therapeutic approaches for depression encompass the administration of serotonin reuptake inhibitors, monoamine oxidase inhibitors, and tricyclic antidepressants, albeit these pharmaceuticals potentially induce adverse neurological and gastrointestinal effects. Traditional Chinese Medicine (TCM) natural products proffer the benefits of multi-target, multi-level, and multi-channel depression treatment modalities. In this investigation, we conducted a comprehensive literature review of the past 5 years in PubMed and other databases utilizing the search terms "Depression," "Natural medicines," "Traditional Chinese Medicine," and "hypothalamic-pituitary-adrenal axis." We delineated the 5 most recent and pertinent signaling pathways associated with depression and hypothalamic-pituitary-adrenal (HPA) axis dysregulation: nuclear factor kappa light-chain-enhancer of activated B cell, brain-derived neurotrophic factor, mitogen-activated protein kinase, cyclic AMP/protein kinase A, and phosphoinositide 3-kinase/protein kinase B. Additionally, we deliberated the antidepressant mechanisms of natural medicines comprising alkaloids, flavonoids, polyphenols, saponins, and quinones via diverse pathways. This research endeavor endeavored to encapsulate and synthesize the progression of TCMs in modulating HPA axis-associated signaling pathways to mitigate depression, thereby furnishing robust evidence for ensuing research in this domain.
Identifiants
pubmed: 37932977
doi: 10.1097/MD.0000000000035862
pii: 00005792-202311030-00009
pmc: PMC10627670
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e35862Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–312.
Mansourian M, Khademi S, Marateb HR. A comprehensive review of computer-aided diagnosis of major mental and neurological disorders and suicide: a biostatistical perspective on data mining. Diagnostics (Basel). 2021;11:393.
Guo Y, Sun J, Hu S, et al. Hospitalization costs and financial burden on families with children with depression: a cross-section study in Shandong Province, China. Int J Environ Res Public Health. 2019;16:3526.
Bassil K, Krontira AC, Leroy T, et al. In vitro modeling of the neurobiological effects of glucocorticoids: a review. Neurobiol Stress. 2023;23:100530.
Bangsgaard EO, Ottesen JT. Patient specific modeling of the HPA axis related to clinical diagnosis of depression. Math Biosci. 2017;287:24–35.
Perez-Caballero L, Torres-Sanchez S, Romero-López-Alberca C, et al. Monoaminergic system and depression. Cell Tissue Res. 2019;377:107–13.
de Kloet ER, Derijk RH, Meijer OC. Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat Clin Pract Endocrinol Metab. 2007;3:168–79.
Rohleder N, Wolf JM, Wolf OT. Glucocorticoid sensitivity of cognitive and inflammatory processes in depression and posttraumatic stress disorder. Neurosci Biobehav Rev. 2010;35:104–14.
Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73:114–26.
Waters RP, Rivalan M, Bangasser DA, et al. Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci Biobehav Rev. 2015;58:63–78.
Zhou L, Wang T, Yu Y, et al. The etiology of poststroke-depression: a hypothesis involving HPA axis. Biomed Pharmacother. 2022;151:113146.
Spielmans GI, Spence-Sing T, Parry P. Duty to warn: antidepressant black box suicidality warning is empirically justified. Front Psychiatry. 2020;11:18.
Sharma T, Guski LS, Freund N, et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016;352:i65.
He MC, Feng R, Wang J, et al. Prevention and treatment of natural products from Traditional Chinese Medicine in depression: potential targets and mechanisms of action. Front Aging Neurosci. 2022;14:950143.
Zhang Y, Han M, Liu Z, et al. Chinese herbal formula xiao yao san for treatment of depression: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2012;2012:931636.
Man C, Li C, Gong D, et al. Meta-analysis of Chinese herbal Xiaoyao formula as an adjuvant treatment in relieving depression in Chinese patients. Complement Ther Med. 2014;22:362–70.
Sheng CX, Chen ZQ, Cui HJ, et al. Is the Chinese medicinal formula Guipi Decoction () effective as an adjunctive treatment for depression? A meta-analysis of randomized controlled trials. Chin J Integr Med. 2017;23:386–95.
Yeung WF, Chung KF, Ng KY, et al. A meta-analysis of the efficacy and safety of traditional Chinese medicine formula Ganmai Dazao decoction for depression. J Ethnopharmacol. 2014;153:309–17.
Zhang X, Kang D, Zhang L, et al. Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. Aging Ment Health. 2014;18:941–53.
Nedic Erjavec G, Sagud M, Nikolac Perkovic M, et al. Depression: biological markers and treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2021;105:110139.
Giridharan S, Srinivasan M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J Inflamm Res. 2018;11:407–19.
Singh A, Martinez-Yamout MA, Wright PE, et al. Interactions of a long noncoding RNA with domains of NF-κB and IκBα: implications for the inhibition of non-signal-related phosphorylation. Biochemistry. 2022;61:367–76.
Srinivasan M, Walker C. Circadian clock, glucocorticoids and NF-κB signaling in neuroinflammation- implicating glucocorticoid induced leucine zipper as a molecular link. ASN Neuro. 2022;14:17590914221120190.
Wang Y, Gao J, Yu Y, et al. A plant-derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy. Br J Pharmacol. 2023;180:194–213.
Yang S, Magnutzki A, Alami NO, et al. IKK2/NF-κB activation in astrocytes reduces amyloid β deposition: a process associated with specific microglia polarization. Cells. 2021;10:2669.
Dong Y, Hong W, Tang Z, et al. Dexmedetomidine attenuates neurotoxicity in developing rats induced by sevoflurane through upregulating BDNF-TrkB-CREB and downregulating ProBDNF-P75NRT-RhoA signaling pathway. Mediators Inflamm. 2020;2020:5458061.
Hennings JM, Kohli MA, Uhr M, et al. Polymorphisms in the BDNF and BDNFOS genes are associated with hypothalamus-pituitary axis regulation in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109686.
Chen H, Amazit L, Lombès M, et al. Crosstalk between glucocorticoid receptor and early-growth response protein 1 accounts for repression of brain-derived neurotrophic factor transcript 4 expression. Neuroscience. 2019;399:12–27.
Wang R, Yan F, Liao R, et al. Role of brain-derived neurotrophic factor and nerve growth factor in the regulation of Neuropeptide W in vitro and in vivo. Mol Cell Endocrinol. 2017;447:71–8.
Hu W, Wu J, Ye T, et al. Farnesoid X receptor-mediated cytoplasmic translocation of CRTC2 disrupts CREB-BDNF signaling in hippocampal CA1 and leads to the development of depression-like behaviors in mice. Int J Neuropsychopharmacol. 2020;23:673–86.
Flores K, Yadav SS, Katz AA, et al. The nuclear translocation of mitogen-activated protein kinases: molecular mechanisms and use as novel therapeutic target. Neuroendocrinology. 2019;108:121–31.
Wang JQ, Mao L. The ERK pathway: molecular mechanisms and treatment of depression. Mol Neurobiol. 2019;56:6197–205.
Numakawa T, Odaka H, Adachi N, et al. Basic fibroblast growth factor increased glucocorticoid receptors in cortical neurons through MAP kinase pathway. Neurochem Int. 2018;118:217–24.
Li X, Qi SM, Wang Y, et al. Antidepressant effect of electroacupuncture on modulating the expression of c-Fos/AP-1 through the JNK signaling pathway. Anat Rec (Hoboken). 2021;304:2480–93.
Zhou X, Yi W, Zhi Y, et al. Stress-activated protein kinase JNK modulates depression-like behaviors in mice. Mol Neurobiol. 2023;60:2367–78.
Kv A, Madhana RM, Js IC, et al. Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. Behav Brain Res. 2018;344:73–84.
Pramanik R, Qi X, Borowicz S, et al. p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem. 2003;278:4831–9.
Zou H, Shi M, He F, et al. Expression of corticotropin releasing hormone in olive flounder (Paralichthys olivaceus) and its transcriptional regulation by c-Fos and the methylation of promoter. Comp Biochem Physiol B Biochem Mol Biol. 2021;251:110523.
Ji CH, Gu JH, Liu Y, et al. Hippocampal MSK1 regulates the behavioral and biological responses of mice to chronic social defeat stress: involving of the BDNF-CREB signaling and neurogenesis. Biochem Pharmacol. 2022;195:114836.
Zeyen L, Seternes OM, Mikkola I. Crosstalk between p38 MAPK and GR signaling. Int J Mol Sci. 2022;23:3322.
Gao F, Yang S, Wang J, et al. cAMP-PKA cascade: an outdated topic for depression? Biomed Pharmacother. 2022;150:113030.
Inda C, Bonfiglio JJ, Dos Santos Claro PA, et al. cAMP-dependent cell differentiation triggered by activated CRHR1 in hippocampal neuronal cells. Sci Rep. 2017;7:1944.
Zhu C, Hui L, Zheng K, et al. Silencing of RGS2 enhances hippocampal neuron regeneration and rescues depression-like behavioral impairments through activation of cAMP pathway. Brain Res. 2020;1746:147018.
Agarwal A, Halvorson LM, Legradi G. Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res. 2005;138:45–57.
Adachi N, Suzuki S, Matsuoka H, et al. Corticotropin-releasing hormone-binding protein is up-regulated by brain-derived neurotrophic factor and is secreted in an activity-dependent manner in rat cerebral cortical neurons. J Neurochem. 2018;146:99–110.
Cai MY, Yang Z, Huang XJ, et al. Mongolian medicine areca thirteen pill (GY-13) improved depressive syndrome via upregulating cAMP/PKA/CREB/BDNF signaling pathway. J Ethnopharmacol. 2022;293:115310.
Detka J, Ślusarczyk J, Kurek A, et al. Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line. Pharmacol Rep. 2019;71:338–46.
Bergantin LB. Depression rises the risk of hypertension incidence: discussing the link through the Ca2+/cAMP signalling. Curr Hypertens Rev. 2020;16:73–8.
Ebner M, Lučić I, Leonard TA, et al. PI(3,4,5)P(3) engagement restricts Akt activity to cellular membranes. Mol Cell. 2017;65:416–431.e6.
Losenkov IS, Vyalova NM, Simutkin GG, et al. An association of AKT1 gene polymorphism with antidepressant treatment response. World J Biol Psychiatry. 2016;17:239–42.
Jacobi D. Old pathways - new crossroads: class 3 PI3K acts on glucocorticoid signal transduction. Acta Physiol (Oxf). 2022;235:e13812.
Liu B, Zhang Y, Yang Z, et al. ω-3 DPA protected neurons from neuroinflammation by balancing microglia M1/M2 polarizations through inhibiting NF-κB/MAPK p38 signaling and activating neuron-BDNF-PI3K/AKT pathways. Mar Drugs. 2021;19:587.
Liu S, Xu S, Wang Z, et al. Anti-depressant-like effect of sinomenine on chronic unpredictable mild stress-induced depression in a mouse model. Med Sci Monit. 2018;24:7646–53.
Li X, Liu C, Jiang B, et al. The antidepressant-like effects of sinomenine in mice: a behavioral and neurobiological characterization. Behav Pharmacol. 2018;29:306–15.
Zhang M, Wang XL, Shi H, et al. Betaine inhibits NLRP3 inflammasome hyperactivation and regulates microglial M1/M2 phenotypic differentiation, thereby attenuating lipopolysaccharide-induced depression-like behavior. J Immunol Res. 2022;2022:9313436.
Xian YF, Ip SP, Li HQ, et al. Isorhynchophylline exerts antidepressant-like effects in mice via modulating neuroinflammation and neurotrophins: involvement of the PI3K/Akt/GSK-3β signaling pathway. FASEB J. 2019;33:10393–408.
Zhan Y, Han J, Xia J, et al. Berberine suppresses mice depression behaviors and promotes hippocampal neurons growth through regulating the miR-34b-5p/miR-470-5p/BDNF axis. Neuropsychiatr Dis Treat. 2021;17:613–26.
Li W, Yin N, Tao W, et al. Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-κB and p38 signaling. Int Immunopharmacol. 2019;66:82–90.
Sur B, Lee B. Myricetin inhibited fear and anxiety-like behaviors by HPA axis regulation and activation of the BDNF-ERK signaling pathway in posttraumatic stress disorder rats. Evid Based Complement Alternat Med. 2022;2022:8320256.
Tantipongpiradet A, Monthakantirat O, Vipatpakpaiboon O, et al. Effects of puerarin on the ovariectomy-induced depressive-like behavior in ICR mice and its possible mechanism of action. Molecules. 2019;24:4569.
Achour M, Ferdousi F, Sasaki K, et al. Luteolin modulates neural stem cells fate determination: in vitro study on human neural stem cells, and in vivo study on LPS-induced depression mice model. Front Cell Dev Biol. 2021;9:753279.
Cao LH, Qiao JY, Huang HY, et al. PI3K-AKT signaling activation and icariin: the potential effects on the perimenopausal depression-like rat model. Molecules. 2019;24:3700.
Zheng XX, Chen YW, Yue YS, et al. Icariin ameliorates learning and memory impairments through ERK/CaMKIIα/CREB signaling and HPA axis in prenatally stressed female offspring. Biomed Pharmacother. 2019;117:109077.
Zheng M, Liu C, Pan F, et al. Antidepressant-like effect of hyperoside isolated from Apocynum venetum leaves: possible cellular mechanisms. Phytomedicine. 2012;19:145–9.
Sun Y, Zhang H, Wu Z, et al. Quercitrin rapidly alleviated depression-like behaviors in lipopolysaccharide-treated mice: the involvement of PI3K/AKT/NF-κB signaling suppression and CREB/BDNF signaling restoration in the hippocampus. ACS Chem Neurosci. 2021;12:3387–96.
Filho CB, Jesse CR, Donato F, et al. Neurochemical factors associated with the antidepressant-like effect of flavonoid chrysin in chronically stressed mice. Eur J Pharmacol. 2016;791:284–96.
Liu Z, Zou Y, He M, et al. Hydroxysafflor yellow A can improve depressive behavior by inhibiting hippocampal inflammation and oxidative stress through regulating HPA axis. J Biosci. 2022;47:7.
Yu H, Fan C, Yang L, et al. Ginsenoside Rg1 prevents chronic stress-induced depression-like behaviors and neuronal structural plasticity in rats. Cell Physiol Biochem. 2018;48:2470–82.
Sur B, Lee B. Ginsenoside Rg3 modulates spatial memory and fear memory extinction by the HPA axis and BDNF-TrkB pathway in a rat post-traumatic stress disorder. J Nat Med. 2022;76:821–31.
Liang W, Liu Y, Zhou K, et al. Ginsenoside Rb1 prevents lipopolysaccharide-induced depressive-like behavior by inhibiting inflammation and neural dysfunction and F2 elicits a novel antidepressant-like effect: a metabolite-based network pharmacology study. J Ethnopharmacol. 2022;282:114655.
Jiang N, Jingwei L, Wang H, et al. Ginsenoside 20(S)-protopanaxadiol attenuates depressive-like behaviour and neuroinflammation in chronic unpredictable mild stress-induced depressive rats. Behav Brain Res. 2020;393:112710.
Dong SQ, Zhang QP, Zhu JX, et al. Gypenosides reverses depressive behavior via inhibiting hippocampal neuroinflammation. Biomed Pharmacother. 2018;106:1153–60.
Hong H, Lu X, Wu C, et al. A review for the pharmacological effects of paeoniflorin in the nervous system. Front Pharmacol. 2022;13:898955.
Zhang W, Zhang F, Hu Q, et al. The emerging possibility of the use of geniposide in the treatment of cerebral diseases: a review. Chin Med. 2021;16:86.
Huang J, Ye Y, Xiao Y, et al. Geniposide ameliorates glucocorticoid-induced osteoblast apoptosis by activating autophagy. Biomed Pharmacother. 2022;155:113829.
Chen XQ, Chen SJ, Liang WN, et al. Saikosaponin A attenuates perimenopausal depression-like symptoms by chronic unpredictable mild stress. Neurosci Lett. 2018;662:283–9.
Su J, Pan YW, Wang SQ, et al. Saikosaponin-d attenuated lipopolysaccharide-induced depressive-like behaviors via inhibiting microglia activation and neuroinflammation. Int Immunopharmacol. 2020;80:106181.
Zheng X, Cheng Y, Chen Y, et al. Ferulic acid improves depressive-like behavior in prenatally-stressed offspring rats via anti-inflammatory activity and HPA axis. Int J Mol Sci. 2019;20.
Li G, Wang G, Shi J, et al. trans-Resveratrol ameliorates anxiety-like behaviors and fear memory deficits in a rat model of post-traumatic stress disorder. Neuropharmacology. 2018;133:181–8.
Lu R, Zhang L, Wang H, et al. Echinacoside exerts antidepressant-like effects through enhancing BDNF-CREB pathway and inhibiting neuroinflammation via regulating microglia M1/M2 polarization and JAK1/STAT3 pathway. Front Pharmacol. 2022;13:993483.
Bai Y, Song L, Dai G, et al. Antidepressant effects of magnolol in a mouse model of depression induced by chronic corticosterone injection. Steroids. 2018;135:73–8.
Wang C, Gan D, Wu J, et al. Honokiol exerts antidepressant effects in rats exposed to chronic unpredictable mild stress by regulating brain derived neurotrophic factor level and hypothalamus-pituitary-adrenal axis activity. Neurochem Res. 2018;43:1519–28.
Lu J, Zhou H, Meng D, et al. Tanshinone IIA improves depression-like behavior in mice by activating the ERK-CREB-BDNF signaling pathway. Neuroscience. 2020;430:1–11.
Kim W, Kwon HJ, Jung HY, et al. Neuroprotective effects of purpurin against ischemic damage via MAPKs, bax, and oxidative stress cascades in the gerbil hippocampus. Mol Neurobiol. 2022;59:2580–92.
Wang YS, Shen CY, Jiang JG. Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery. Pharmacol Res. 2019;150:104520.
Wang B, Chen X, Zhou T, et al. Antidepressant-like effects of embelin and its possible mechanisms of action in chronic unpredictable stress-induced mice. Neurol Res. 2018;40:666–76.
Lin B, Xu P, Zheng J, et al. Effects and mechanisms of natural alkaloids for prevention and treatment of osteoporosis. Front Pharmacol. 2022;13:1014173.
Shang XF, Yang CJ, Morris-Natschke SL, et al. Biologically active isoquinoline alkaloids covering 2014-2018. Med Res Rev. 2020;40:2212–89.
Munir S, Shahid A, Aslam B, et al. The therapeutic prospects of naturally occurring and synthetic indole alkaloids for depression and anxiety disorders. Evid Based Complement Alternat Med. 2020;2020:8836983.
Hamid HA, Ramli AN, Yusoff MM. Indole alkaloids from plants as potential leads for antidepressant drugs: a mini review. Front Pharmacol. 2017;8:96.
Santos-Buelga C, Feliciano AS. Flavonoids: from structure to health issues. Molecules. 2017;22:477.
Malla AM, Dar BA, Isaev AB, et al. Flavonoids: a reservoir of drugs from nature. Mini Rev Med Chem. 2023;23:772–86.
Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonols/flavonoids in neurodegeneration and neuroinflammation. Mini Rev Med Chem. 2020;20:1475–88.
German-Ponciano LJ, Rosas-Sánchez GU, Rivadeneyra-Domínguez E, et al. Advances in the preclinical study of some flavonoids as potential antidepressant agents. Scientifica (Cairo). 2018;2018:2963565.
Pannu A, Sharma PC, Thakur VK, et al. Emerging role of flavonoids as the treatment of depression. Biomolecules. 2021;11:1825.
Khan H, Perviz S, Sureda A, et al. Current standing of plant derived flavonoids as an antidepressant. Food Chem Toxicol. 2018;119:176–88.
Passos FRS, Araújo-Filho HG, Monteiro BS, et al. Anti-inflammatory and modulatory effects of steroidal saponins and sapogenins on cytokines: a review of pre-clinical research. Phytomedicine. 2022;96:153842.
Chen XM, Lin GX, Wang X, et al. Beneficial effects of ginsenosides on diabetic nephropathy: a systematical review and meta-analysis of preclinical evidence. J Ethnopharmacol. 2023;302(Pt A):115860.
Luong Huynh D, Nguyen NH, Nguyen CT. Pharmacological properties of ginsenosides in inflammation-derived cancers. Mol Cell Biochem. 2021;476:3329–40.
Jakobek L, Blesso C. Beneficial effects of phenolic compounds: native phenolic compounds vs metabolites and catabolites. Crit Rev Food Sci Nutr. 2023:1–19.
Shi R, Gao D, Stoika R, et al. Potential implications of polyphenolic compounds in neurodegenerative diseases. Crit Rev Food Sci Nutr. 2022:1–24.
Akter R, Rahman H, Behl T, et al. Prospective role of polyphenolic compounds in the treatment of neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2021;20:430–50.
Ying HZ, Yu CH, Chen HK, et al. Quinonoids: therapeutic potential for lung cancer treatment. Biomed Res Int. 2020;2020:2460565.
Nguyen TTH, Pandey RP, Parajuli P, et al. Microbial synthesis of non-natural anthraquinone glucosides displaying superior antiproliferative properties. Molecules. 2018;23:2171.
Xin D, Li H, Zhou S, et al. Effects of anthraquinones on immune responses and inflammatory diseases. Molecules. 2022;27:3831.
Zhang L, Zhang G, Xu S, et al. Recent advances of quinones as a privileged structure in drug discovery. Eur J Med Chem. 2021;223:113632.
Ma L, Hu P, Zhang J, et al. Purpurin exerted antidepressant-like effects on behavior and stress axis reactivity: evidence of serotonergic engagement. Psychopharmacology (Berl). 2020;237:887–99.
Safari M, Asadi A, Aryaeian N, et al. The effects of melissa officinalis on depression and anxiety in type 2 diabetes patients with depression: a randomized double-blinded placebo-controlled clinical trial. BMC Complement Med Ther. 2023;23:140.
Ebrahimi H, Mardani A, Basirinezhad MH, et al. The effects of Lavender and Chamomile essential oil inhalation aromatherapy on depression, anxiety and stress in older community-dwelling people: a randomized controlled trial. Explore (NY). 2022;18:272–8.
Akhondzadeh S, Mostafavi SA, Keshavarz SA, et al. A placebo controlled randomized clinical trial of Crocus sativus L (saffron) on depression and food craving among overweight women with mild to moderate depression. J Clin Pharm Ther. 2020;45:134–43.
Kolahdooz G, Vosough I, Sepahi S, et al. The effect of crocin versus sertraline in treatment of mild to moderate postpartum depression: a double-blind, randomized clinical trial. Int Clin Psychopharmacol. 2023;38:9–15.
Bangratz M, Ait Abdellah S, Berlin A, et al. A preliminary assessment of a combination of rhodiola and saffron in the management of mild-moderate depression. Neuropsychiatr Dis Treat. 2018;14:1821–9.
Yang L, Di YM, Shergis JL, et al. A systematic review of acupuncture and Chinese herbal medicine for postpartum depression. Complement Ther Clin Pract. 2018;33:85–92.
Yu JJ, Pei LB, Zhang Y, et al. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2015;35:406–10.
Panahi Y, Badeli R, Karami GR, et al. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res. 2015;29:17–21.
Ahmad S, Azhar A, Tikmani P, et al. A randomized clinical trial to test efficacy of chamomile and saffron for neuroprotective and anti-inflammatory responses in depressive patients. Heliyon. 2022;8:e10774.
Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33:504–23.
Sharifi-Rad J, Herrera-Bravo J, Salazar LA, et al. The therapeutic potential of wogonin observed in preclinical studies. Evid Based Complement Alternat Med. 2021;2021:9935451.
Wang G, Wang Y, Yao L, et al. Pharmacological activity of quercetin: an updated review. Evid Based Complement Alternat Med. 2022;2022:3997190.
Nam W, Nam SH, Kim SP, et al. Anti-adipogenic and anti-obesity activities of purpurin in 3T3-L1 preadipocyte cells and in mice fed a high-fat diet. BMC Complement Altern Med. 2019;19:364.
He T, Lin X, Su A, et al. Mitochondrial dysfunction-targeting therapeutics of natural products in Parkinson’s disease. Front Pharmacol. 2023;14:1117337.
Gaston TE, Mendrick DL, Paine MF, et al. “Natural” is not synonymous with “Safe”: toxicity of natural products alone and in combination with pharmaceutical agents. Regul Toxicol Pharmacol. 2020;113:104642.
Burke NN, Coppinger J, Deaver DR, et al. Sex differences and similarities in depressive- and anxiety-like behaviour in the Wistar-Kyoto rat. Physiol Behav. 2016;167:28–34.
Dadomo H, Gioiosa L, Cigalotti J, et al. What is stressful for females? Differential effects of unpredictable environmental or social stress in CD1 female mice. Horm Behav. 2018;98:22–32.
Chen Q, Ruan D, Shi J, et al. The multifaceted roles of natural products in mitochondrial dysfunction. Front Pharmacol. 2023;14:1093038.
Noviana E, Indrayanto G, Rohman A. Advances in fingerprint analysis for standardization and quality control of herbal medicines. Front Pharmacol. 2022;13:853023.